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Introduction {#sec005}
============

Down syndrome (DS) is the most prevalent chromosomal abnormality, with approximately 5.4 million affected individuals worldwide \[[@pone.0232596.ref001]\], with 206,000 of these patients in the United States \[[@pone.0232596.ref002]\]. In the last decades, the life expectancy of individuals with DS has considerably increased and currently exceeds 60 years in developed countries. \[[@pone.0232596.ref001]\] A common comorbidity in people with DS is obstructive sleep apnea (OSA), whose prevalence ranges from 78 to 100% in adults \[[@pone.0232596.ref003]--[@pone.0232596.ref008]\] and 69% to 76% in children \[[@pone.0232596.ref009]\]. Moreover, when compared to the general population, the OSA is more often classified as severe and is associated with more significant hypoxemia in individuals with DS. \[[@pone.0232596.ref003]\] In turn, OSA-related hypoxemia has been associated with decreased verbal IQ, executive function, visual-perceptual skills and increase in mood disorders in patients with DS. \[[@pone.0232596.ref010]\]

The higher prevalence and severity of OSA in patients with DS is related to the phenotypic characteristics of DS itself. These changes include upper airway hypotonia, midface hypoplasia, mandibular hypoplasia, glossoptosis, lingual tonsil hypertrophy, pharyngomalacia, laryngomalacia, and tonsil / adenoid hypertrophy. Additionally, factors such as obesity and hypothyroidism, which are also frequently observed in individuals with DS, favor OSA onset. \[[@pone.0232596.ref003],[@pone.0232596.ref010],[@pone.0232596.ref011]\]

Despite the high risk for OSA in individuals with DS, recommendations for OSA screening and polysomnography in this population are not well established. The American Academy of Pediatrics recommends that polysomnography be performed in all children with DS up to the age of 4, or earlier, if OSA symptoms are present. \[[@pone.0232596.ref012]\] As for adult patients with DS, the recommendation is also to perform OSA screening, but it is not clearly defined how the screening should be performed (e.g., using a questionnaire or through polysomnography), nor the periodicity of this screening (e.g., annual or biannual assessment). Another important issue is that, for the adult population with DS, there are no validated questionnaires for OSA screening and there is no specific recommendation on which questionnaire should be applied to this special group of patients.

Considering that in the overall population, adequate OSA treatment helps to reduce the incidence of comorbidities and improve neurocognitive functions \[[@pone.0232596.ref013]\], the identification of OSA in patients with DS is essential to ensure a better neurological prognosis.

Therefore, the aim of the present study was to evaluate OSA prevalence and factors associated with OSA severity in adult patients with DS. Moreover, we investigated which questionnaire is the most appropriate for OSA screening in this population.

Methods and materials {#sec006}
=====================

This study was carried out from October 2017 to October 2018 and included 66 adults with DS attending the Down Syndrome Reference Center (CRISDOWN) of Hospital Regional da Asa Norte (HRAN) linked to Faculdade de Medicina da Escola Superior de Ciências da Saúde (ESCS), Brasília, Federal District, Brazil.

Subjects were sequentially recruited and submitted to type III polysomnography, anthropometric data collection, laboratory tests and sleep assessment questionnaires.

The inclusion criteria comprised individuals with DS treated at our service, of both genders, good overall health status, aged 18 years and older, capable to understand and accept the study and its procedures. The following were excluded: (1) individuals under 18 years of age; (2) patients undergoing treatment for sleep disorders; (3) patients with a history of conditions that could affect brain structure or function (such as cerebrovascular accident or head trauma); (4) those who refused to participate in the study.

A researcher explained the study in details to all participants with DS and their proxies. Those who agreed to participate in the study signed the free and informed written consent form. The study was approved by the Research Ethics Committee of Fundação de Ensino e Pesquisa em Ciências da Saúde (FEPECS) according to Opinion number 1,656,332/2016 and followed the principles established by the Declaration of Helsinki.

Data collection and research protocol {#sec007}
-------------------------------------

After the study participants were defined, a structured interview was carried out to collect the following data: age, gender, BMI, neck circumference (NC), Mallampati class and comorbidities. Venous blood samples were obtained for analysis after a fasting period of 12 to 15 hours. Laboratory tests included complete blood count, thyroid stimulating hormone (TSH), fasting glucose, HOMA-IR, alanine aminotransferase (ALT), uric acid, urea, creatinine and sodium levels.

The following questionnaires were also applied for sleep assessment: Epworth Sleepiness Scale (ESS) \[[@pone.0232596.ref014],[@pone.0232596.ref015]\], Pittsburgh Sleep Quality Index (PSQI) \[[@pone.0232596.ref016]\], BERLIN Questionnaire (BQ) \[[@pone.0232596.ref017],[@pone.0232596.ref018]\], and the STOP-Bang Questionnaire (SBQ) \[[@pone.0232596.ref019],[@pone.0232596.ref020]\].

In the sleep assessment questionnaires, due to the absence of cutoff points specifically defined for the adult population with DS, the ones defined for the overall population were used, as follows: (1) probable presence of excessive daytime sleepiness in the ESS (total score\> 10) \[[@pone.0232596.ref014]\]; (2) poor sleep quality in the PSQI (total score \>5) \[[@pone.0232596.ref016]\]; (3) risk for OSA in the BQ (two or more positive categories) \[[@pone.0232596.ref017]\]; (4) risk for OSA in the SBQ (3 or more affirmative answers) \[[@pone.0232596.ref019]\]. These questionnaires were answered by the patients' proxies, in agreement with other studies in individuals with DS. \[[@pone.0232596.ref004],[@pone.0232596.ref005],[@pone.0232596.ref021]\]

Moreover, all research subjects underwent type III polysomnography according to international guidelines. \[[@pone.0232596.ref022]\] This type III polysomnography has been previously used in OSA studies in individuals with DS \[[@pone.0232596.ref023]\] and in other populations \[[@pone.0232596.ref024],[@pone.0232596.ref025]\].

In the present study, the equipment used to perform the type III PSG assessments was the ApneaLink Air (ResMed Germany Inc.), which has been previously used in other important studies. \[[@pone.0232596.ref024],[@pone.0232596.ref025]\] This equipment allowed monitoring with the use of nasal pressure cannula (for airflow and snore detection), chest piezoelectric strap (for respiratory effort detection) and pulse oximetry (to monitor peripheral arterial oxygen saturation---SpO~2~ and heart rate).

The total recording time was used as the denominator to calculate the respiratory event index (REI). \[[@pone.0232596.ref022],[@pone.0232596.ref026]\] The PSG was assembled by a specialized technician from the Sleep Laboratory of our service. The patient was then referred to a temperature-controlled and quiet bedroom, to undergo the all-night test, without the technician's supervision. All patients were accompanied by a proxy during the examination, who slept in a separate bed, but in the same room. Recording of sleep examination records started at 8pm and stopped at 7am in the following morning.

The respiratory events were defined as follows: (1) hypopnea, when there was a ≥30% reduction in airflow for at least 10 seconds, observed through the nasal cannula, associated with a decrease in SpO~2~ of at least 3%; (2) obstructive apnea, due to the absence or reduction ≥ 90% of airflow for at least 10 seconds in the presence of respiratory effort; (3) mixed apnea, due to the absence or reduction ≥ 90% of airflow, without the presence of respiratory effort only at the beginning of the event; (4) central apnea, due to absence or ≥ 90% reduction in airflow for at least 10 seconds associated with absence of respiratory effort throughout the event. \[[@pone.0232596.ref027]\]

The OSA was then classified as mild, moderate or severe. It was classified as mild OSA when the REI was between 5 and 14.9 events / hour, moderate when the REI was between 15 and 29.9 events / hour and severe when the REI was 30 or more events / hour (detected by type III polysomnography). \[[@pone.0232596.ref027]\]

The polysomnography exams were manually reviewed by a single physician according to AASM standardized criteria. \[[@pone.0232596.ref027]\] The examiner was blinded to any patient clinical data. The PSG examinations were considered valid when there was ≥ 4 hours of adequate recording without significant loss of sensor signal (nasal pressure cannula, pulse oximetry and chest strap). \[[@pone.0232596.ref028]--[@pone.0232596.ref030]\]

Statistical analysis {#sec008}
--------------------

Numerical data are presented as mean and standard deviation. Categorical data are presented as absolute numbers and percentage. The statistical analysis was initially performed with simple (univariate) linear regression analysis to identify factors correlated with REI. Subsequently, variables with p-values \<0.15 were considered for the multiple linear regression analysis, using variable selection according to the backward technique. A p-value \<0.05 was used as the criterion for the retention of variables in the final multiple linear regression model. \[[@pone.0232596.ref031],[@pone.0232596.ref032]\] Logarithmic transformation was used to obtain the dependent variable distribution normalization. Assumptions of normality, homocedascity (constant variance) and residual independence were assessed. The presence of multicollinearity was assessed by estimating the variance inflation factor (VIF), with VIF \>5 being used as an indication of multicollinearity in the multiple linear regression analysis. \[[@pone.0232596.ref032]\]

The adjusted coefficient of determination R^2^ was used as a measure of fit quality. Normality was assessed by visual inspection of histograms and by applying the Shapiro-Wilk normality test. \[[@pone.0232596.ref033],[@pone.0232596.ref034]\]

The sleep questionnaires that remained in the final multiple linear regression analysis model were used as categorical variable (positive or negative questionnaire) together with moderate to severe OSA (present or absent) in 2x2 contingency tables. Consequently, odds ratio (OR), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated.

The R software (R Foundation, Vienna, Austria) was used for statistical data analysis. \[[@pone.0232596.ref033],[@pone.0232596.ref034]\] All hypothesis tests were bilateral. Values of p \<0.05 were considered significant.

Results {#sec009}
=======

During the study period, 66 adults with DS were included in the research. Of this total, 60 completed and 06 patients (9%) dropped out of the study out of their own will. Ten percent (6 subjects) had to undergo the PSG again due to technical problems, such as loss of signal from one of the sensors.

[Table 1](#pone.0232596.t001){ref-type="table"} shows the participants' demographic characteristics (N = 60). A total of 33 men (55%) and 27 women (45%) participated in the study and the mean age of the sample was 27.7 ± 9.1 years. Obesity and overweight were observed in 27 (45%) and 14 (23%) subjects, respectively. Oropharyngeal examination showed that 52 (86%) participants were Mallampati class III or IV. Clinically, 30 individuals (50%) were diagnosed with congenital heart disease, and 7 had undergone previous surgical correction.

10.1371/journal.pone.0232596.t001

###### Clinical and laboratory characteristics of adult participants with Down syndrome.

![](pone.0232596.t001){#pone.0232596.t001g}

  Variable                   Overall
  -------------------------- -------------
  Age, years                 27.7± 9.1
  Gender, Male sex           33 (55%)
  BMI, kg/m^2^               27.9 ± 5.9
  Overweight                 14 (23%)
  Obesity                    27 (45%)
  Neck circumference, cm     40 ± 3.7
  Mallampati class, 3--4     52 (86%)
  Hypothyroidism             40 (66%)
  Congenital cardiopathies   30 (50%)
  Uric acid                  6.2 ±1.5
  Creatinine                 0.96 ± 0.18
  Glucose                    63.9 ± 34.4
  Hematocrit                 47.7 ± 5.4
  HOMA-IR                    6.3 ± 6.2
  Sodium                     140.1 ± 2.9
  ALT                        23.1 ± 10.1
  TSH                        2.6 ± 1.8
  Urea                       29.6 ± 11.2

Values are shown as mean ± SD, N (%). SD = standard deviation, BMI = body mass index, ALT = alanine aminotransferase, TSH = thyroid stimulating hormone. N = 60.

Regarding the questionnaires used for sleep assessment ([Table 2](#pone.0232596.t002){ref-type="table"}) it was observed that: (1) ESS suggested sleepiness (ESS \>10) in 32 participants (53%); (2) PSQI identified sleep disorders (PSQI \>5) in 37 participants (61%); (3) the BQ and (4) the SBQ indicated high risk of OSA in 49 participants (81%) and 55 participants (91%), respectively.

10.1371/journal.pone.0232596.t002

###### Sleep-related characteristics of adult participants with Down syndrome.

![](pone.0232596.t002){#pone.0232596.t002g}

  Variable                             Overall
  ------------------------------------ ------------
  REI                                  30.4 ± 19
  OSA severity                         
      Mild                             11 (18.3%)
      Moderate                         26 (43.3%)
      Severe                           23 (38.3%)
  \(1\) ESS score                      10.8 ± 3.9
      Total score \> 10                32 (53%)
  \(2\) PSQI score                     6.4 ± 2.2
      Total score \> 5                 37 (61%)
  \(3\) BQ score, risk for OSA         49 (81%)
  \(4\) SBQ score, risk for OSA (≥3)   55 (91%)

Values are shown as mean ± SD, N (%). SD = standard derivation, REI = respiratory event index, BMI = body mass index., BQ = Berlin Questionnaire, ESS = Epworth Sleepiness Scale, PSQI = Pittsburgh Sleep Quality Index, SBQ = Stop-Bang Questionnaire. N = 60.

When performing the type III PSG, it was observed that the 60 (100%) study individuals had OSA (REI ≥ 5 events / h), with moderate to severe OSA in 49 (81.6%). Central sleep apnea syndrome (\> 5 events / h) was not observed in any of the subjects.

At the simple linear regression analysis ([Table 3](#pone.0232596.t003){ref-type="table"}), several variables showed a significant linear association with the dependent variable (REI), such as uric acid, glucose, hematocrit, HOMA-IR, BMI, ALT, neck circumference, Mallampati class, BQ, ESS, PSQI and SBQ. However, the multiple linear regression analysis (final model), as shown in [Table 4](#pone.0232596.t004){ref-type="table"}, identified only hematocrit, BMI and SBQ as independent predictors of REI. On average, for every 1-unit increase in the hematocrit or BMI variables, and for SBQ to go from negative to positive, the REI response variable increased by 0.073, 0.028, and 0.616 respectively. None of the other sleep questionnaire scores (BQ, ESS, and PSQI) demonstrated a significant positive linear association with REI.

10.1371/journal.pone.0232596.t003

###### Results of simple (univariate) linear regression analysis for the dependent variable respiratory event index.

![](pone.0232596.t003){#pone.0232596.t003g}

  Covariate                  Level       Regression coefficient (Beta)   95%CI Lower   95%CI Upper   P-value
  -------------------------- ----------- ------------------------------- ------------- ------------- --------------------------------------------------
  Uric acid                              0.230                           0.149         0.312         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  Creatinine                             0.637                           -0.235        1.509         0.149
  Glucose                                0.024                           0.011         0.036         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  Hematocrit                             0.082                           0.062         0.102         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  HOMA-IR                                0.054                           0.032         0.075         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  Age                                    0.014                           -0.003        0.031         0.102
  BMI                                    0.034                           0.009         0.059         **0.01**[\*](#t003fn002){ref-type="table-fn"}
  Sodium                                 0.038                           -0.015        0.090         0.157
  ALT                                    0.023                           0.008         0.037         **0.003**[\*](#t003fn002){ref-type="table-fn"}
  TSH                                    -0.047                          -0.134        0.041         0.288
  Urea                                   0.012                           -0.002        0.026         0.083
  Congenital cardiopathies   Yes         0.037                           -0.278        0.352         0.814
  No                         \-          \-                              \-            **-**         
  BQ score                   Positive    0.795                           0.446         1.145         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  Negative                   \-          \-                              \-            **-**         
  ESS score                  ESS \> 10   0.081                           0.046         0.116         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  \-                         \-          \-                              \-                          
  PSQI score                 PSQI \> 5   0.072                           0.005         0.139         **0.037**[\*](#t003fn002){ref-type="table-fn"}
  \-                         \-          \-                              \-            **-**         
  SBQ score                  ≥3          0.958                           0.447         1.469         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  0--2                       \-          \-                              \-            **-**         
  Neck circumference                     0.051                           0.010         0.092         **0.016**[\*](#t003fn002){ref-type="table-fn"}
  Mallampati class           3/4         0.837                           0.430         1.245         **\< .001**[\*](#t003fn002){ref-type="table-fn"}
  1/2                        \-          \-                              \-            **-**         
  Hypothyroidism             Yes         0.058                           -0.276        0.392         0.729
  No                         \-          \-                              \-            **-**         
  Number of drugs used       ≥ 2         0.312                           -0.051        0.675         0.091
  0/1                        \-          \-                              \-            **-**         
  Gender                     Female      -0.227                          -0.538        0.084         0.149
  Male                       \-          \-                              \-            **-**         

BMI = body mass index, ALT = alanine aminotransferase, TSH = thyroid stimulating hormone, BQ = Berlin Questionnaire, ESS = Epworth Sleepiness Scale, PSQI = Pittsburgh Sleep Quality Index, SBQ = Stop-Bang Questionnaire.

\*Statistical significance = p \< 0.05. N = 60 in each of the simple linear regression analyses.

10.1371/journal.pone.0232596.t004

###### Results of the multivariate linear regression analysis for the dependent variable respiratory event index.

![](pone.0232596.t004){#pone.0232596.t004g}

                        REI                     
  ------------ -------- ------- ------- ------- --------------------------------------------------
  Hematocrit            0.073   0.056   0.090   **\< .001**[\*](#t004fn002){ref-type="table-fn"}
  BMI                   0.028   0.013   0.043   **\< .001**[\*](#t004fn002){ref-type="table-fn"}
  SBQ          \> = 3   0.616   0.289   0.943   **\< .001**[\*](#t004fn002){ref-type="table-fn"}
               0--2     \-      \-      \-      **-**

REI = respiratory event index, BMI = body mass index, SBQ = Stop-Bang Questionnaire. Adj R-Sq = 0.69.

\* Statistical significance. N = 60.

As the SBQ remained in the final multiple linear regression model, the contingency table analysis (2x2) with moderate-severe OSA was performed. Positive SBQ (3 or more affirmative answers) showed in the screening of moderate-severe OSA, 100% of sensitivity (95%CI: 92.75--100%), 45.45% of specificity (95%CI: 16.75--76.62%), 89.09% of PPV (95%CI: 82.64--93.34%), 100% of NPV, 90% of accuracy (95%CI: 79.49--96.24%) and OR of 24.29.

Discussion {#sec010}
==========

The present study contributes with important findings. First, when compared to previously published studies \[[@pone.0232596.ref003]--[@pone.0232596.ref008]\], it included the largest number of adults with DS. Second, it evaluated for the first time the role of the SBQ in moderate-severe OSA screening in this population. Moreover, this was the first study to evaluate the prevalence of OSA in DS adults in Brazil.

Thus, we demonstrated that the prevalence of OSA in individuals with DS in our sample was 100%. Moreover, 81.6% of the subjects had moderate to severe OSA. Interestingly, participants with DS were included in the present study regardless of whether or not they had significant complaints of sleep-disordered breathing. This fact supports the idea of performing active OSA screening in all adult individuals with DS during routine consultations \[[@pone.0232596.ref003],[@pone.0232596.ref005]\]. Compared to other OSA studies in adult individuals with DS, the prevalence of OSA was also high and ranged from 78 to 100%. It is noteworthy that the number of individuals included in such studies was usually small, the smallest with 3 patients and the largest with 47 individuals \[[@pone.0232596.ref003]--[@pone.0232596.ref008]\]. The difference in OSA prevalence between studies possibly derives from heterogeneities between them, such as different types of polysomnography for OSA diagnosis, as well as sample characterization and size.

Our results also demonstrated that BMI is positively related with OSA severity indicated by the REI. This finding corroborates the high prevalence of the observed moderate-severe OSA, based on the fact that 68% of our adult patients with DS were obese or overweight. This correlation between BMI and REI has been well documented in the overall population \[[@pone.0232596.ref035]\] and in adults with DS \[[@pone.0232596.ref003],[@pone.0232596.ref005],[@pone.0232596.ref006]\].

Interestingly, the hematocrit level is also related with OSA severity (REI). This relation has been previously identified in individuals in the overall population with OSA \[[@pone.0232596.ref036],[@pone.0232596.ref037]\]; however, it had not yet been demonstrated in the population of DS adults. This relation possibly reflects the presence and greater severity of nocturnal hypoxemia that stimulates increased erythropoietin synthesis, with consequent elevated erythrocyte production and increased hematocrit levels \[[@pone.0232596.ref036],[@pone.0232596.ref037]\].

Besides, our study also showed the relation between higher SBQ score and higher REI (OSA severity) in DS adults. This relation has been widely shown in the general population \[[@pone.0232596.ref038]--[@pone.0232596.ref040]\]. As an example, a recent meta-analysis study demonstrated that the higher the SBQ score, the greater the likelihood of moderate-severe OSA \[[@pone.0232596.ref038]\].

Regarding the use of sleep questionnaires for OSA screening, our study was the first to identify a questionnaire capable of playing a significant role in moderate-severe OSA screening in DS adults. The sensitivity and accuracy of the SBQ for detecting moderate-severe OSA was 100% and 90%, respectively.

This result indicates that the SBQ should be applied to all adult individuals with DS, thus helping to prioritize individuals who need to undergo the polysomnography. This recommendation becomes important as we observe that the international guidelines indicate OSA screening in adults with DS, but do not clearly indicate how this screening should be performed \[[@pone.0232596.ref041]--[@pone.0232596.ref044]\].

Finally, regarding the results of the BQ, ESS and PSQI questionnaires not showing a role in relation to OSA in our study, they are in accordance with the results of the study by Giménez et al \[[@pone.0232596.ref005]\].

Our study shows some limitations. First, the individuals were submitted to a type III PSG and not to a full PSG test. Consequently, we did not have information related to sleep architecture, and OSA severity (REI) may have been underestimated. However, the type III PSG has been used in DS with good results. \[[@pone.0232596.ref023],[@pone.0232596.ref045]--[@pone.0232596.ref047]\] Moreover, the number of technical problems that required the type III PSG to be repeated was small (10% in our study), which is in accordance to previous studies in DS or not (3--18%). \[[@pone.0232596.ref022],[@pone.0232596.ref023],[@pone.0232596.ref047]--[@pone.0232596.ref049]\]

Another limitation of the present study is the absence of DS adults without OSA. Since the present study was performed in a single center for DS patients from a reference hospital and did not include patients treated in a community care institution, our results may represent a specific population of DS adults, with more comorbidities. Moreover, considering that the prevalence of DS patients without OSA should be quite low, it will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals \[[@pone.0232596.ref005]\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78--100% \[[@pone.0232596.ref003]--[@pone.0232596.ref008]\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies \[[@pone.0232596.ref005],[@pone.0232596.ref050]\]. The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20--29 years and 30--39 years \[[@pone.0232596.ref051]\]. The prevalence in these healthy adult individuals was 7.4% and 24.2%, respectively \[[@pone.0232596.ref051]\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS \[[@pone.0232596.ref052],[@pone.0232596.ref053]\], which have recently been described as essential measures to decrease OSA-related symptoms in the population general \[[@pone.0232596.ref054]--[@pone.0232596.ref058]\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia \[[@pone.0232596.ref054]--[@pone.0232596.ref058]\]. All these aspects are critical points in the population with DS. The impact of these exercises should be more important in childhood. In general, there is an improvement in the severity of OSA throughout childhood, and the earlier the diagnosis and treatment of OSA is started, the less the possible damage to health, and the better the general quality of life and longevity of people with DS \[[@pone.0232596.ref010]\]. New studies in the future should address the role of oropharyngeal exercises in DS in childhood and adult.

In addition, since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score ≥ 3) in 6 adults with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA. However, as this is the first study evaluating the role of the SBQ for the screening of moderate-severe OSA in DS adults, further studies are needed for external validation of our findings. Notwithstanding, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is significant since access to polysomnography is limited in the majority of the countries.

Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS. \[[@pone.0232596.ref010]\]

Conclusion {#sec011}
==========

In conclusion, our study confirmed the very high prevalence of OSA in adults with DS. Additionally, the SBQ, hematocrit levels and BMI showed a strong correlation with OSA severity. Furthermore, the SBQ showed high sensitivity and specificity in identifying moderate-severe OSA in this population. Taken together, these results open new horizons to screening OSA in adults with DS. Nevertheless, considering the limited access to polysomnography for all patients, the use of hematocrit levels and BMI, and especially the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo the polysomnography. However, further studies with a larger population of patients with DS are needed for more definitive conclusions to be drawn.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This well written article reports the results of a study aimed at assessing the real incidence of OSA in adults with DS and at investigating whether biochemical analysis and/or questionnaires could help in identifying subjects at higher risk for OSA.

Overall, this paper is well written and well organized, and could certainly be of interest for the readers of the Journal.

I only have a couple of minor points.

There is a brief mention to screening for OSA during childhood. Have the Authors some data on the "stability" of this diagnosis? Are there children with DS and OSA presenting a significant improvement of their symptoms? And how many adults already presented with symptoms during childhood? And in these case, were they recognized, or misdiagnosed? Some of this information could be added for the present series.

A second point is about the percentage of OSA found in this study. Reporting a 100% prevalence of OSA limits the strength of the SBQ as a possible screening test, since it would be interesting to understand the difference in scores between adults with and without OSA, and not only reporting a different severity. This limit should be pointed out and discussed.

Reviewer \#2: this is a very nice manuscript examining the utility of the stop-bang questionnaire in individuals with trisomy 21. overall, it is well conceived and carried out, and adds to the literature.

a few points:

1\. a major limitation is the lack of individuals without osa in the sample.

2\. given \#1, i would suggest to the authors that they emphasize the role of the stop-bang in potentially differentiating mild from mod/severe osa in their sample, as there may be differences in associated comorbidity.

3\. in the results section, especially the last paragraph, recommend being very clear about what the predictive values are actually predicting (i.e. mod/severe osa or just any osa?).

\*\*\*\*\*\*\*\*\*\*
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Author response to Decision Letter 0

3 Mar 2020

To Andrea Romigi, MD, Ph.D

Academic Editor

PLOS ONE

Dear Editor

Thank you for considering the paper: "STOP-Bang questionnaire should be used in all adults with Down Syndrome to screen for moderate to severe obstructive sleep apnea" (PONE-D-19-26496)" by Carvalho et al., for publication in the PLOS ONE.

Thank you for allowing us to re-submit this revised manuscript.

We would also like to thank all the reviewers for their positive comments and helpful criticisms of our paper.

We hope that we answered all the queries, which certainly improved the quality of the manuscript, making the article more suitable to contribute to the relevance of OSA in adults with Down Syndrome (DS).

We are looking forward to your decision regarding the suitability of the revised version of this paper for the Journal.

Thank you very much in advance,

Sincerely,

Anderson Albuquerque de Carvalho

AUTHORS' REPLY TO REVIEWER'S \#1 COMMENTS

Q- 1. There is a brief mention to screening for OSA during childhood. Have the Authors some data on the "stability" of this diagnosis? Are there children with DS and OSA presenting a significant improvement of their symptoms?

Answer to query Q1:

We thank the Reviewer for constructive criticism. No, unfortunately, we do not have any data for OSA in childhood. On the other hand, we think that is an important issue to be discussed in the manuscript.

Concerning the \"stability\" of the diagnosis in children with DS, in a recent meta-analysis, the prevalence and severity of OSA in children with DS that OSA (AHI\> 1, 1.5 or 2 events / h) was highly prevalent, affecting 69% to 76% of children with DS\[9\]. Besides, approximately half of these children (50%) had moderate to severe OSA (AHI\> 5 events / h). In particular, this meta-analysis concluded that some children with DS had moderate to severe OSA at their young ages.

Concerning whether children with DS and OSA present a significant improvement in their symptoms, some studies addressed this question. In general, there is an improvement in the severity of OSA throughout childhood and, the earlier the diagnosis and treatment of OSA is started, the less the possible damage to health, the better the general quality of life and longevity of people with DS\[10\]. Soon, this high prevalence of OSA in DS patients, even in childhood, may be reduced with early stimulation that includes oropharyngeal exercises in DS \[35,36\], which has recently been used as essential measures for problems related to OSA in the general population\[37-41\]. These exercises improve OSA by reducing the circumference of mouth breathing and the neck and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. All these aspects are critical points in the population with DS.

We have included a paragraph in the text that provides information on the prevalence and improvement of symptoms of OSA in children with DS. The new text is marked in yellow and was inserted in the introduction and discussion.

Introduction

"A common comorbidity in people with DS is obstructive sleep apnea (OSA), whose prevalence ranges from 78 to 100% in adults\[3-8\] and 69% to 76% in children \[9\]."

Discussion

"Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as important measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. All these aspects are critical points in the population with DS. The impact of these exercises should be more important in childhood. In general, there is an improvement in the severity of OSA throughout childhood, and the earlier the diagnosis and treatment of OSA is started, the less the possible damage to health, and the better the general quality of life and longevity of people with DS\[10\]. New studies in the future should address the role of oropharyngeal exercises in DS in childhood and adult."

Q- 2. And how many adults already presented with symptoms during childhood? And in these case, were they recognized, or misdiagnosed? Some of this information could be added for the present series.

Answer to query Q2:

We thank the reviewer for this observation. This is another very important issue to be studied. However, we did not investigate the symptoms and diagnosis of OSA in childhood. In fact, we did not find in the literature studies carried out in the adult population with DS that investigated the presence of OSA symptoms in childhood. Notwithstanding, that is a good idea and, since we continue the study enrolling new patients, we will add this question in the interview. Unfortunately, we did not have a sleep disorder unit for childhood. We are trying to set up this unit and, your comment encourages us to continue our demand to the Brazilian authorities.

Q- 3. A second point is about the percentage of OSA found in this study. Reporting a 100% prevalence of OSA limits the strength of the SBQ as a possible screening test, since it would be interesting to understand the difference in scores between adults with and without OSA, and not only reporting a different severity. This limit should be pointed out and discussed.

Answer to query Q3:

We thank the reviewer for the constructive comments. We agree that the absence of adults with DS without OSA is the main limitation of this study. Since the present study was performed in a single center for DS patients from a reference hospital, it is possible that our results may represent a specific population of DS adults, with more comorbidities, since DS patients treated in a community care institution were not included. Moreover, considering that the prevalence of DS patients without OSA should be quite low, It will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals\[5\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78-100%\[3-8\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies\[5,57\].

The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20-29 years and 30-39 years \[58\]. The prevalence in these typical adults individual was 7.4% and 24.2%, respectively\[58\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as important measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. Concerning the comment: "Reporting a 100% prevalence of OSA limits the strength of the SBQ as a possible screening test since it would be interesting to understand the difference in scores between adults with and without OSA, and not only reporting a different severity." We agree that this is another limitation of our study. Since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score \> 3) in 6 patients with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA.

However, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is very important since access to polysomnography is limited in the majority of the countries.

Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS.\[10\]

To improve the quality of the manuscript, we included all these observations in the discussion/conclusion section when we wrote the limitations of the study. They are marked in yellow.

Discussion

Our study shows some limitations. First, the individuals were submitted to a type III PSG and not to a full PSG test. Consequently, we did not have information related to sleep architecture, and OSA severity (REI) may have been underestimated. However, the type III PSG has been used in DS with good results.\[23,50-52\] Moreover, the number of technical problems that required the type III PSG to be repeated was small (10% in our study), which is in accordance to previous studies in DS or not (3--18%).\[22,23,54-56\]

"Another limitation of the present study is the absence of DS adults without OSA. Since the present study was performed in a single center for DS patients from a reference hospital and did not include patients treated in a community care institution, our results may represent a specific population of DS adults, with more comorbidities. Moreover, considering that the prevalence of DS patients without OSA should be quite low, it will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals\[5\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78-100%\[3-8\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies\[5,57\]. The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20-29 years and 30-39 years \[58\]. The prevalence in these healthy adult individuals was 7.4% and 24.2%, respectively\[58\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as essential measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. All these aspects are critical points in the population with DS. The impact of these exercises should be more important in childhood. In general, there is an improvement in the severity of OSA throughout childhood, and the earlier the diagnosis and treatment of OSA is started, the less the possible damage to health, and the better the general quality of life and longevity of people with DS\[10\]. New studies in the future should address the role of oropharyngeal exercises in DS in childhood and adult."

"In addition, since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score ≥ 3) in 6 adults with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA. However, as this is the first study evaluating the role of the SBQ for the screening of moderate-severe OSA in DS adults, further studies are needed for external validation of our findings. Notwithstanding, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is significant since access to polysomnography is limited in the majority of the countries."

"Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS.\[10\]"

Conclusion

"Furthermore, the SBQ showed high sensitivity and specificity in identifying moderate-severe OSA in this population. Taken together, these results open new horizons to screening OSA in adults with DS."

AUTHORS' REPLY TO REVIEWER'S \#2 COMMENTS

Q- 1. a major limitation is the lack of individuals without osa in the sample.

Answer to query Q1:

We thank the reviewer for the constructive comments. We agree that the absence of adults with DS without OSA is the main limitation of this study. Since the present study was performed in a single center for DS patients from a reference hospital, it is possible that our results may represent a specific population of DS adults, with more comorbidities, since DS patients treated in a community care institution were not included. Moreover, considering that the prevalence of DS patients without OSA should be quite low, It will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals\[5\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78-100%\[3-8\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies\[5,57\].

The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20-29 years and 30-39 years \[58\]. The prevalence in these typical adults individual was 7.4% and 24.2%, respectively\[58\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as important measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. Concerning the comment: "Reporting a 100% prevalence of OSA limits the strength of the SBQ as a possible screening test since it would be interesting to understand the difference in scores between adults with and without OSA, and not only reporting a different severity." We agree that this is another limitation of our study. Since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score \> 3) in 6 patients with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA.

However, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is very important since access to polysomnography is limited in the majority of the countries.

Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS.\[10\]

To improve the quality of the manuscript, we included all these observations in the discussion/conclusion section when we wrote the limitations of the study. They are marked in yellow.

Discussion

Our study shows some limitations. First, the individuals were submitted to a type III PSG and not to a full PSG test. Consequently, we did not have information related to sleep architecture, and OSA severity (REI) may have been underestimated. However, the type III PSG has been used in DS with good results.\[23,50-52\] Moreover, the number of technical problems that required the type III PSG to be repeated was small (10% in our study), which is in accordance to previous studies in DS or not (3--18%).\[22,23,54-56\]

"Another limitation of the present study is the absence of DS adults without OSA. Since the present study was performed in a single center for DS patients from a reference hospital and did not include patients treated in a community care institution, our results may represent a specific population of DS adults, with more comorbidities. Moreover, considering that the prevalence of DS patients without OSA should be quite low, it will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals\[5\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78-100%\[3-8\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies\[5,57\]. The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20-29 years and 30-39 years \[58\]. The prevalence in these healthy adult individuals was 7.4% and 24.2%, respectively\[58\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as essential measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. All these aspects are critical points in the population with DS. The impact of these exercises should be more important in childhood. In general, there is an improvement in the severity of OSA throughout childhood, and the earlier the diagnosis and treatment of OSA is started, the less the possible damage to health, and the better the general quality of life and longevity of people with DS\[10\]. New studies in the future should address the role of oropharyngeal exercises in DS in childhood and adult."

"In addition, since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score ≥ 3) in 6 adults with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA. However, as this is the first study evaluating the role of the SBQ for the screening of moderate-severe OSA in DS adults, further studies are needed for external validation of our findings. Notwithstanding, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is significant since access to polysomnography is limited in the majority of the countries."

"Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS.\[10\]"

Conclusion

"Furthermore, the SBQ showed high sensitivity and specificity in identifying moderate-severe OSA in this population. Taken together, these results open new horizons to screening OSA in adults with DS."

Q- 2. given \#1, i would suggest to the authors that they emphasize the role of the stop-bang in potentially differentiating mild from mod/severe osa in their sample, as there may be differences in associated comorbidity.

Answer to query Q2:

We thank the Reviewer for this observation. We agree and changed the text in the manuscript that emphasize this observation and makes the text clearer to the reader. These modifications are in yellow.

Discussion

"The present study contributes to important findings. First, when compared to previously published studies\[3-8\], the present included the largest number of adults with DS. Second, it evaluated for the first time the role of the SBQ in moderate-severe OSA screening in this population."

"Besides, our study also showed the relation between higher SBQ score and higher REI (OSA severity) in DS adults. This relation has been widely shown in the general population\[45-47\]. As an example, a recent meta-analysis study demonstrated that the higher the SBQ score, the greater the likelihood of moderate-severe OSA\[45\]."

"Regarding the use of sleep questionnaires for OSA screening, our study was the first to identify a questionnaire capable of playing a significant role in moderate-severe OSA screening in DS adults."

Q- 3. in the results section, especially the last paragraph, recommend being very clear about what the predictive values are actually predicting (i.e. mod/severe osa or just any osa?)

Answer to query Q3:

We thank the reviewer for this observation. You are right, and we made changes in the manuscript to turn this aspect more precise.

In Results, we emphasize in the text of the study when the information is related to moderate-severe OSA.

Results

"As the SBQ remained in the final multiple linear regression model, the contingency table analysis (2x2) with moderate-severe OSA was performed. Positive SBQ (3 or more affirmative answers) showed in the screening of moderate-severe OSA, 100% of sensitivity (95%CI: 92.75-100%), 45.45% of specificity (95%CI: 16.75-76.62%), 89.09% of PPV (95%CI: 82.64-93.34%), 100% of NPV, 90% of accuracy (95%CI: 79.49-96.24%) and OR of 24.29."

AUTHORS' REPLY TO ACADEMIC EDITOR

Q- 1. The main limitation is the lack of patient without OSA. The authors should explain this issue and attempt to correlate OSAS severity and Stop Bang score.

Answer to query Q1:

We thank the Academic Editor for the constructive comments. We agree that the absence of adults with DS without OSA is the main limitation of this study. Since the present study was performed in a single center for DS patients from a reference hospital, it is possible that our results may represent a specific population of DS adults, with more comorbidities, since DS patients treated in a community care institution were not included. Moreover, considering that the prevalence of DS patients without OSA should be quite low, It will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals\[5\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78-100%\[3-8\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies\[5,57\].

The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20-29 years and 30-39 years \[58\]. The prevalence in these typical adults individual was 7.4% and 24.2%, respectively\[58\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as important measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. Concerning the comment: "Reporting a 100% prevalence of OSA limits the strength of the SBQ as a possible screening test since it would be interesting to understand the difference in scores between adults with and without OSA, and not only reporting a different severity." We agree that this is another limitation of our study. Since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score \> 3) in 6 patients with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA.

However, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is very important since access to polysomnography is limited in the majority of the countries.

Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS.\[10\]

To improve the quality of the manuscript, we included all these observations in the discussion/conclusion section when we wrote the limitations of the study. They are marked in yellow.

Discussion

Our study shows some limitations. First, the individuals were submitted to a type III PSG and not to a full PSG test. Consequently, we did not have information related to sleep architecture, and OSA severity (REI) may have been underestimated. However, the type III PSG has been used in DS with good results.\[23,50-52\] Moreover, the number of technical problems that required the type III PSG to be repeated was small (10% in our study), which is in accordance to previous studies in DS or not (3--18%).\[22,23,54-56\]

"Another limitation of the present study is the absence of DS adults without OSA. Since the present study was performed in a single center for DS patients from a reference hospital and did not include patients treated in a community care institution, our results may represent a specific population of DS adults, with more comorbidities. Moreover, considering that the prevalence of DS patients without OSA should be quite low, it will be necessary to increase the sample size, and, at some point, a small number of adults without OSA would be identified. Interestingly, so far, the largest study that evaluated OSA in adults DS patients included 47 individuals\[5\] reported a prevalence of 78% of OSA. Therefore, the high prevalence of OSA observed in our DS patients is similar to what was described in other studies, which varies between 78-100%\[3-8\]. It is conceivable that the absence of adults with DS without OSA is possibly related to the high prevalence of overweight and obesity observed in our patients, which was 68%. Nevertheless, a similar prevalence of overweight and obesity was described by other studies\[5,57\]. The prevalence of OSA observed in the present study in DS patients is significantly higher than the general adult population of São Paulo, Brazil, in a similar age, between 20-29 years and 30-39 years \[58\]. The prevalence in these healthy adult individuals was 7.4% and 24.2%, respectively\[58\]. Also, in the near future, this high prevalence of OSA can reduce in DS patients with early stimulation that includes oropharyngeal exercises in DS\[35,36\], which have recently been described as essential measures to decrease OSA-related symptoms in the population general\[37-41\]. These exercises improve OSA by reducing the circumference of mouth and neck breathing and improving lip hypotonia, the resting position of the tongue, and hypotonia\[37-41\]. All these aspects are critical points in the population with DS. The impact of these exercises should be more important in childhood. In general, there is an improvement in the severity of OSA throughout childhood, and the earlier the diagnosis and treatment of OSA is started, the less the possible damage to health, and the better the general quality of life and longevity of people with DS\[10\]. New studies in the future should address the role of oropharyngeal exercises in DS in childhood and adult."

"In addition, since we do not have DS patients without OSA, we cannot extend the Stop-Bang score for these patients. Nevertheless, SBQ can be a useful tool to exclude patients without moderate-severe OSA in the DS population, since negative SBQ (score \< 3) was not observed in moderate-severe OSA. In contrast, we observed positive SBQ (score ≥ 3) in 6 adults with mild OSA. Consequently, it is plausible that positive SBQ may occur in DS patients without OSA. However, as this is the first study evaluating the role of the SBQ for the screening of moderate-severe OSA in DS adults, further studies are needed for external validation of our findings. Notwithstanding, the main finding of the study is that the application of the SBQ can select the individuals at higher risk for moderate-severe OSA who should undergo polysomnography. This result is significant since access to polysomnography is limited in the majority of the countries."

"Considering that the treatment of moderate-severe OSA indicates specific interventions such as the use of positive airway pressure (PAP) or even some type of surgical intervention, the identification of these patients is essential to ensure an improvement in the quality of life, longevity, and reduction of morbidities associated with OSA in people with DS.\[10\]"

Conclusion

"Furthermore, the SBQ showed high sensitivity and specificity in identifying moderate-severe OSA in this population. Taken together, these results open new horizons to screening OSA in adults with DS."
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